Comparative Pharmacology
Head-to-head clinical analysis: TRANSDERM SCOP versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRANSDERM SCOP versus ZUPLENZ.
TRANSDERM SCOP vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the vestibular system, gastrointestinal tract, and central nervous system, inhibiting vagal nerve activity and preventing motion-induced nausea and vomiting.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
One transdermal patch (1 mg/72 hours) applied to the hairless area behind the ear at least 4 hours before anticipated exposure; replace every 72 hours as needed.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
The terminal elimination half-life of scopolamine is approximately 9.5 hours (range 6-12 hours) following transdermal administration. In elderly patients, half-life may be prolonged to up to 20 hours.
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Scopolamine is extensively metabolized; about 50% of a dose is excreted renally as metabolites and unchanged drug, with less than 10% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 30-40% of the dose.
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category C
Category C
Antiemetic
Antiemetic